Physician profile
Shailendra Singh
NPI 1750520300
$66,921.93
in general payments reported to CMS, 2019-2025
34 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,403 · 2020: $1,217 · 2021: $1,357 · 2022: $1,820 · 2023: $3,725 · 2024: $2,792 · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $14K · Food and Beverage: $8,164 · Travel and Lodging: $8,053 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,540.00 |
| Consulting Fee | $14,260.00 |
| Food and Beverage | $8,163.73 |
| Travel and Lodging | $8,052.88 |
| Education | $107.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $33,963.09 | 2019-2025 | Bimzelx, Cimzia, Rystiggo |
| Amgen INC. | $20,524.63 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Horizon Therapeutics Plc | $3,387.55 | 2019-2023 | Krystexxa |
| Hoffmann-La Roche Limited | $1,469.75 | 2023 | |
| Janssen Biotech, INC. | $1,357.66 | 2019-2025 | Simponi Aria, Tremfya, Simponi |
| Abbvie INC. | $1,014.34 | 2019-2025 | Rinvoq |
| Ucb Sa | $1,007.75 | 2024 | |
| Glaxosmithkline, LLC. | $932.33 | 2019-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $650.88 | 2020-2025 | Acthar |
| Genentech USA, INC. | $521.15 | 2021-2025 | Actemra, Gazyva |
| Novartis Pharmaceuticals Corporation | $457.31 | 2023-2025 | |
| Pfizer INC. | $346.84 | 2019-2025 | |
| Organon LLC | $145.33 | 2022-2025 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $128.97 | 2019 | |
| Janssen Scientific Affairs, LLC | $124.99 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.88 | 2019-2025 | Ofev |
| Novo Nordisk INC | $93.64 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $82.08 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $77.39 | 2024-2025 | Orencia |
| Celgene Corporation | $64.16 | 2019 | |
| Lilly USA, LLC | $60.98 | 2023-2024 | Taltz |
| Alexion Pharmaceuticals, INC. | $52.98 | 2021 | |
| Lundbeck LLC | $52.83 | 2023 | Vyepti |
| Shockwave Medical, INC | $52.27 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $48.03 | 2024 | Xarelto |
| Sobi, INC | $44.75 | 2025 | |
| Pacira Therapeutics, INC. | $42.93 | 2020-2021 | |
| Aurinia Pharma U.S., INC. | $28.46 | 2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $26.36 | 2023 | Opsumit, Uptravi |
| Radius Health, INC. | $17.75 | 2020 | |
| Fresenius Kabi USA, LLC | $13.29 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $12.58 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shailendra Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.